HSP90AB1 and cancer: Most of them are based on low-molecular weight drugs (e.g., geldanamycin and its derivatives, synthetic compounds) blocking the intracellular ATPase activity of Hsp90 and thus suppressing multiple oncogenic pathways of cancer development [26,27,28,29].